VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the company's partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera® (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17-22, 2026 in San Diego, CA. “We are pleased to see the continued clinical progress of zanidatamab reflected in multiple presentations at AACR,” said Ken Galbraith, Chair, Chief Executive Officer, and Interim Chief Financial Officer of Zymeworks.
